2016 Archived Content

Dinner Short Courses*


14 NOVEMBER, 19:00 - 21:30

Dinner Provided

(SC1) Humanized Mouse Models: Technology and Applications in Preclinical Assessment of Cancer Immunotherapy - Detailed Agenda

Humanized mouse models have been developed as immunologically relevant models for preclinical profiling of cancer immunotherapies. The course will describe different types of humanized mouse models, their immune characterization, and specific examples of their application in the field of Cancer Immunotherapy. The course will highlight advantages and pitfalls of currently available humanized mouse models and will give an overview of the next generation improved humanized models designed to better address specific immunological questions.

Agenda:

  • How to select the best humanized mouse model for specific immunotherapeutic applications
  • Immunopharmacodynamic analyses in humanized mice: Impact of immunotherapeutic treatments on the immune cell contexture
  • Humanized mouse models: In-house generation or outsourcing?

Instructors:
Sara Colombetti, Ph.D., Group Leader Immunopharmacodynamics and Pharmacokinetics, Pharmacology Department, Roche Innovation Center Zürich
Christian Gerdes, Ph.D., Head of Pharmacology, Roche Pharma Research & Early Development, Roche


15 NOVEMBER, 18:30 - 21:00

Dinner Provided

(SC2) New Technologies for Improving Drug Safety Screening - Detailed Agenda

This course will bring together experts who will discuss the use of new technologies and platforms for early, predictive drug safety screening. Focus will be on the use and validation of induced pluripotent stem cells (iPSC), 3D cell cultures and organ-on-a-chip systems. The course will be conducted in an informal, interactive setting and will provide attendees with ample time for networking and asking questions.

Agenda:

From Simple to Complex in vitro Models of the Liver

  • The importance of understanding the phenotype of models - Otherwise they are black boxes
  • Progress - From 2D liver cancer cell lines to primary liver cells, cultured as simple single cell models, to 3D, to complex, multicell models, incorporating flow, etc.

Use of Different hiPSC-Cardiomyocyte-Based Technologies in Early Derisking

  • Insights in the pros and cons of different stem cell technologies for cardiovascular safety research
  • Some real case example(s) of stem cell readouts in a CV derisking flow chart

Design Rules and Fabrication Issues for Organ-on-a-Chip Systems

  • 2D vs. 3D, what are the issues?
  • How best to design and build multi-organ human systems
  • What are the regulatory issues for these systems?

Instructors:
Christopher Goldring, Ph.D., Professor, Molecular and Cellular Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, U.K.
James J. Hickman, Ph.D., Founding Director, NanoScience Technology Center and Professor, Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering, University of Central Florida
Ard C.H. Teisman, Ph.D., Scientific Director, Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development


15 NOVEMBER, 18:30 - 21:00

Dinner Provided

(SC3) Functional Screening Strategies Using CRISPR and RNAi - Detailed Agenda

This course will offer details on how the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas technology works, how to set up CRISPR-based screens and how to complement it with existing RNAi-based screens using proper analysis and follow-up studies. The instructors will share their experiences on how to go about evaluating reagents/libraries, designing and setting up assays, and interpreting results when dealing with complex biology and informatics. The applications of such functional genomics screens for drug discovery and disease modeling will be discussed, along with design and workflows when working with different model systems. Ideas and best practices will be shared in an informal, interactive setting and attendees will walk away with practical advice and resources.

Agenda:

  • Identification of drug targets and phenotypes for essential genes
  • Screen design/common pitfalls
  • Optimized protocols for sample prep, sequencing, and analysis
  • Development of screening models for drug enhancers, re-sensitization screens
  • Requirements of screening models for successful large-scale pooled screening
  • Analysis tools for CRISPR screens

Instructors:
Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University
Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center
Kaylene J. Simpson, Ph.D., Associate Professor and Head, Victorian Centre for Functional Genomics ACRF Translational RPPA Platform, Peter MacCallum Cancer Centre, Australia


*Separate Registration Required


WPE-CAG-Web